About the study

The purpose of this Japan-only study is to assess the safety and efficacy of etrasimod at 2 doses in Japanese subjects with moderately to severely active ulcerative colitis (UC) when administered for 12 weeks.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Japanese ancestry
2. Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening
3. Having active UC confirmed by endoscopy
4. Moderately to severely active UC

Exclusion criteria

1. Severe extensive colitis
2. Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence, history of a fistula consistent with CD
3. Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.